2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one...

Details 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one... 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one...

2005-02-01

2009-02-24

Berch, Mark L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S227800, C514S236500, C514S252020, C514S252030, C540S524000, C544S006000, C544S007000, C544S070000, C544S114000, C544S230000, C544S238000, C549S462000, C562S459000, C562S463000

Reexamination Certificate

active

07494990

ABSTRACT:
The compounds of a certain formula (1),in which R1, R2, R3 and R9 have the meanings as given in the description, are novel effective PDE4 inhibitors.

REFERENCES:
patent: 5267027 (1993-11-01), Ugaki et al.
patent: 5434149 (1995-07-01), Jonas et al.
patent: 5747489 (1998-05-01), Jonas et al.
patent: 5859008 (1999-01-01), Jonas et al.
patent: 6103718 (2000-08-01), Sterk
patent: 6225303 (2001-05-01), Miller et al.
patent: 6380196 (2002-04-01), Ulrich et al.
patent: 6399611 (2002-06-01), Jonas et al.
patent: 6544993 (2003-04-01), Sterk
patent: 6756371 (2004-06-01), Sterk
patent: 6933296 (2005-08-01), Sterk
patent: 6953853 (2005-10-01), Grundler et al.
patent: 7022696 (2006-04-01), Grundler et al.
patent: 2004/0127707 (2004-07-01), Sterk
patent: 2006/0094710 (2006-05-01), Sterk
patent: 2006/0166995 (2006-07-01), Sterk
patent: 2006/0167001 (2006-07-01), Sterk
patent: 0 539 806 (1993-05-01), None
patent: 0 618 201 (1994-10-01), None
patent: 0 723 962 (1996-07-01), None
patent: 0 738 715 (1996-10-01), None
patent: 0 763 534 (1997-03-01), None
patent: 93/07146 (1993-04-01), None
patent: 98/31674 (1998-07-01), None
patent: 99/31071 (1999-06-01), None
patent: 99/31090 (1999-06-01), None
patent: 99/47505 (1999-09-01), None
patent: 01/19818 (2001-03-01), None
patent: 01/30766 (2001-05-01), None
patent: 01/30777 (2001-05-01), None
patent: 01/94319 (2001-12-01), None
patent: 02/064584 (2002-08-01), None
patent: 02/085885 (2002-10-01), None
patent: 02/085906 (2002-10-01), None
patent: 03/032993 (2003-04-01), None
patent: WO 2004018451 (2003-08-01), None
patent: 2004/017957 (2004-03-01), None
patent: 2004/017974 (2004-03-01), None
patent: 2004/018449 (2004-03-01), None
patent: 2004/018450 (2004-03-01), None
patent: 2004/018451 (2004-03-01), None
patent: 2005/075437 (2005-08-01), None
patent: 2005/075457 (2005-08-01), None
Dyke, et al., Exp. Opin. Invest. Drugs 8:1301-1325 (1999).
Hanifin, et al., Journal of Investigative Dermatology, 107(1 ):51-56 (1996).
MacKenzie, Alergology International (2004) 53:101-110.
Sasaki, et al., Inflamm. Res., 53 (2004), 031-037.
European Respiratory Society, Feb. 13, 2007, http://www.newtocopd.com/currentaffairsnews/list751—item17680.aspx, downloaded Jan. 16, 2008.
Lipworth, Lancet, vol. 365: Iss. 9454, 167-175, 2005.
Barnes, Thorax, 2003: 58, pp. 803-808.
Dyke, Exp. Opin. Invest. Drugs (1999) 8(9), 1301-1325.
Kawasaki, et al., Allergology International, vol. 54, No. 3, 2005, pp. 427-433 (abst.).
Baumer, et al., Inflamm Allergy Drug Targets, Mar. 2007; 6(1), 17-26 (abst.).
Coates, W.J., et al., “1,4-Bis (3-oxo-2,3-dihydropyridazin-6-yl)benzene Analogues: Potent Phosphodiesterase Inhibitors and Inodilators”,J. Med. Chem.,vol. 33, pp. 1735-1741, (1990).
Van der Mey, M., et al., “Relationships of 4-Aryl-Substitutedcis-Tetra- andcis-Hexahydrophthalazinones”,J. Med. Chem.,vol. 44, No. 16, pp. 2523-2535, (2001).
Van der Mey, M., et al., “Novel Selective PDE4 Inhibitors. 1. Synthesis, Structure-Activity Relationships, and Molecular Modeling of 4-(3,4-Dimethoxyphenyl)-2H-phthalazin-1-ones and Analogues”,J. Med. Chem.,vol. 44, No. 16, pp. 2511-2522, (2001).
Van der Mey, M., et al., “Novel Selective PDE4 Inhibitors. 3. In Vivo Antiinfalammatory Activity of a New Series of N-Substitutedcis-Tetra- andcis-Hexahydrophthalazinones”,J. Med. Chem.,vol. 45, No. 12, pp. 2520-2525, (2002).
Van der Mey, M., et al., “Novel Selective Phosphodiesterase (PDE4) Inhibitors. 4. Resolution, Absolute Configuration, and PDE4 Inhibitory Activity ofcis-Tetra- andcis-Hexahydrophthalazinones”,J. Med. Chem.,vol. 45, No. 12, pp. 2526-2533, (2002).
Norman, P., “PDE4 inhibitors 2001. Patent and literature activity 2000—Sep. 2001”,Expert Opin. Ther. Patents, vol. 12, No. 1, pp. 93-111, (2002).
Grootendorst, et al. “Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease”,Current Opinion in Allergy and Clinical Immunology, (2002), vol. 2, pp. 61-67.
Souness, et al. “Immunosuppresive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors”,Immunopharmacology47 (2000) pp. 127-162.

Affiliated with

Also associated with

Rating

2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4063373